The rising demand for cold chain logistics in pharma and how Fynd delivers it

India's GLP-1 market is expected to grow about five times by 2030 - from Rs 1,000-1,200 crore in 2025 to nearly Rs 5,000 crore. This means many more injectable medicines need to stay cold while being shipped across many more locations than before.

Most GLP-1 drugs - Ozempic, Wegovy, Mounjaro require refrigeration at 2°C to 8°C from the factory to the patient's door. Insulin, vaccines and other biologics also need this. If the cold chain breaks, the medicine loses effectiveness without showing visible damage - no broken seals or dents, just medicine that does not work properly.

This is why India's pharma logistics is rushing to build cold chain infrastructure faster than ever. And this is exactly the problem Fynd was created to solve.

The industry just admitted this is a big deal

Here is what is happening now and what it shows about the future.

India’s cold chain market - food and pharma logistics made nearly $10.46 billion in 2024 and it is expected to grow seven times by 2033. Pharma cold chain logistics is growing fast as more temperature-sensitive drugs enter the market.

A main cause: the patent cliff. Over 40 major branded drugs will lose patent protection in India from 2026 to 2030. This pushes Indian companies toward biologics, GLP-1 analogs and specialty injectables, all needing strict 2°C to 8°C control. This pressures a cold chain built mostly for oral tablets, not sensitive injectables.

India is not just a buyer but also a global supplier. Eli Lilly has invested in manufacturing in Hyderabad to secure its GLP-1 supply. India supplies 60% of UNICEF’s vaccines globally and meets 40-70% of demand for DPT and BCG vaccines, so vaccine cold chain capacity is already key. Now GLP-1 drugs add volume and complexity.

There’s also a unique compliance challenge in India. Exporting temperature-sensitive drugs means the whole journey inside India must meet Good Distribution Practice (GDP) standards, the same as international legs. This forces Indian pharma logistics to improve quickly.

India’s last-mile delivery is especially tough: Over 13,850 pincodes in 27-28 states, many hard to reach, with multiple stockist levels causing delays and few temperature-controlled delivery outside big cities. Delivering cold chain medicine to small towns is very different from metros.

Together, the rising GLP-1 demand, patent cliff, India’s export role and a tricky last-mile cold chain logistics in India are now a must-have for shipping medicine.

Here is the problem with that

Building a cold chain network that covers 13,850+ pincodes, meets GDP compliance for exports, and handles rising GLP-1 and biologics volumes is hard. Most pharma brands, startups, and regional distributors cannot do this alone. It requires years of investment in refrigerated vehicles, temperature-controlled warehouses and trained staff, mostly owned by a few big logistics firms.

But small and mid-size brands face the same risk: one broken cold chain link can spoil a batch, cause compliance issues, or deliver ineffective medicine to patients in smaller towns.

These brands need a logistics partner with ready infrastructure, technology, and compliance processes across India - a network they can use right away instead of building from scratch.

That is the gap Fynd fills.

How Fynd handles cold chain, without any guesswork

Fynd’s pharma supply chain and cold chain logistics are based on one idea: temperature-sensitive delivery should never be left to chance, wherever in India it goes. Here is how that works.

Real-time temperature monitoring, not just checks at delivery

Most networks check temperature only when a shipment arrives too late or if damage happened. Fynd tracks temperature all along the journey. If it goes outside 2°C-8°C, teams get alerted immediately so they can act before the medicine is spoiled.

Full visibility across India’s complex delivery map

With so many pincodes and stockist layers, shipments can easily get lost in the system. Fynd shows exactly where a package is, its condition and who handled it at every step whether it’s going to Mumbai or a tier-3 town. No guesswork.

Handling tailored to the product

Injectables, tablets, biologics and vaccines all need different care. GLP-1 injectables need tighter temperature control than tablets. Biologics are very sensitive. Fynd’s network knows this and routes, packs and handles each type based on its needs.

GDP compliance built in, not added later

Keeping a drug cold is not enough, you must prove it stayed cold per India’s standards, even for exports. Fynd includes documentation, audit trails and temperature logs in every delivery, so compliance is automatic.

Last-mile delivery beyond big cities

Most cold chain failures happen where temperature-controlled vehicles are rare - outside metros. Fynd’s last-mile service focuses on this gap, making sure handling is right where it matters most.

Scalable without high costs

Building a nationwide cold chain solutins takes years and lots of money. Fynd offers a ready-made network brands can join and scale as GLP-1 and biologics demand grows - no need to build their own.

Data that helps brands improve, not just deliver

Every shipment through Fynd creates data on temperature, delivery times and trouble spots. This helps improve routes and processes so reliability grows as volume grows.

Overall, Fynd is more than a refrigerated truck - it is a system designed for India’s pharma logistics challenges, ensuring safe delivery from metro warehouses to rural homes.

Why the timing matters

The GLP-1 surge is just the start. The 2026-2030 patent cliff will push more makers toward biologics and specialty injectables. India’s role as a global pharma exporter will grow, and cold chain demand will rise fastest in hard-to-reach tier-2 and tier-3 markets.

Brands that act now with the right logistics partner will not scramble later. They will be delivering reliably while others are still building their networks.

So, what should you do next?

India’s pharma cold chain market is growing fast, with more temperature-sensitive drugs, stricter compliance, and challenges in last-mile delivery outside big cities. Fynd is already built for this reality, so pharma and healthcare brands do not have to build it themselves.

If your business ships medicine that cannot warm up, cool down or wait to get to Mumbai or a chemist far away, it is time to ask: is your logistics partner truly ready for this, or just managing?

Is your cold chain ready for the specialty pharma boom? If not, talk to us now!